More on the Rx Front: The slow emergence in the U.S. of biosimilars for curbing specialty costs
Apr 27
Last month we highlighted how both cost and utilization are increasing when it comes to prescription drugs. Much of the increase is due to the rise in specialty medications. This trend is national, across all industries, and continues to be of great concern. The rising costs of medications result in potential barriers for patients’ ability to afford and/or access the drugs they need to be as well as possible.Related to the surge in specialty medications—which often means patients receiving very expensive yet effective, life-altering biologic therapies—it’s helpful to know about the biosimilars that are emerging slowly on the market.Here is some background on this valuable drug product option, which you can expect to read more about in the coming months and years.Defining biosimilarsThe Public Health Safety Act defines biosimilarity to mean, “The biological product is highly similar to...
Read Full Post